Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2021-04-14 Investor Presentation
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
April Investor Call Presentation 24 pages 7.8MB
Investor Presentation Classification · 95% confidence The document is titled 'April Investor Update' and is structured as a presentation with slides, including disclaimers, executive introductions, technology descriptions, pipeline updates, and development milestones. It is clearly intended as an update to investors on the company's business progress, drug development pipeline, and upcoming milestones. There are no detailed financial statements, audit opinions, or regulatory certifications present. The content is typical of an investor presentation focusing on strategy, pipeline, and corporate updates rather than a formal financial report or regulatory filing. Therefore, the document fits best into the category of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2021-04-14 English
Preclinical Data - Superior PPMO Delivery to the Brain 4 pages 2.8MB
Regulatory Filings Classification · 95% confidence The document is a press release dated April 12, 2021, from PYC Therapeutics announcing preclinical data demonstrating superior delivery of their PPMO technology to the brain. It discusses scientific results, research progress, and future plans for drug candidate nomination. There is no indication of financial results, regulatory filings, management changes, or shareholder voting results. The content is focused on scientific and product development updates rather than financial or regulatory reporting. This type of document is best classified as a general regulatory announcement or company update that does not fit into more specific categories like earnings release, annual report, or management information. Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2021-04-11 English
Quarterly Investor Call - 15th April 2021 2 pages 164.0KB
Regulatory Filings Classification · 95% confidence The document is an announcement dated April 6, 2021, from PYC Therapeutics about hosting a quarterly investor call on April 15, 2021. It provides details on the timing, registration, and access to the call, including a note that a recording will be made available after the call. The content focuses on informing investors about the upcoming call rather than providing the transcript or detailed financial data. The document length is 3705 characters, which is relatively short and consistent with an announcement rather than a full transcript or report. There is no substantive financial data or detailed discussion of results, so it is not an Earnings Release or Interim Report. It is not a full transcript of the call, so it is not a Call Transcript. The document is clearly an announcement of an event (investor call) and not the event content itself. Therefore, the most appropriate classification is Investor Presentation (IP) since it is an investor-focused announcement about a call, but given the content is primarily about the call event and not a presentation document, the best fit is Regulatory Filings (RNS) as a general announcement. However, since the call is described as a quarterly investor call with corporate and pipeline updates, and the document is announcing the call, not the presentation itself, the best classification is Regulatory Filings (RNS).
2021-04-05 English
Appendix 3G - Issue of Options 18 pages 309.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement titled 'Appendix 3G – Notification of issue of Equity Securities' related to options issued to a director. It includes detailed information about the entity, the type of securities issued, and complies with ASX reporting requirements for equity securities issuance. There is no financial performance data, earnings information, or management discussion. The document is a regulatory announcement about a capital issuance event, specifically the issuance of options to a director. This fits the category of Capital/Financing Update (CAP) as it relates to company fundraising or capital structure changes through equity securities issuance.
2021-03-29 English
Appendix 3X - Initial Director's Interest Notice 4 pages 232.4KB
Director's Dealing Classification · 95% confidence The document is titled 'Initial Director’s Interest Notice' and references Appendix 3X, which is a standard form used in Australian Securities Exchange (ASX) filings to disclose the interests of newly appointed directors in company securities. The content details the director's name, appointment date, and securities held, consistent with a director's dealing or interest notification. There is no financial data, earnings information, or report content. The document is an announcement of a director's personal share transactions or interests, fitting the category of Director's Dealing (DIRS). The document length is about 5,194 characters, which is sufficient for a detailed notice but not a full financial report. Therefore, the classification is DIRS with high confidence.
2021-03-29 English
PYC Appoints U.S. Biopharma Exec Jason Haddock to its Board 2 pages 168.7KB
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new member to the company's Board of Directors. It details the background and qualifications of the new board member, Jason Haddock, and mentions his role and options granted. There is no financial data, no report or presentation attached, and no mention of voting results or shareholder meetings. The content is focused on management changes at the board level. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 6274 characters, which is sufficient for a detailed announcement but does not contain financial statements or report data.
2021-03-28 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.